Details of the new rules for COVID-19 vaccine approvals were also outlined in an article published by The New England Journal of Medicine, authored by Prasad and FDA Commissioner

The VRBPAC meeting comes the week after the World Health Organization (WHO) recommended that members consider using monovalent JN.1- or KP.2-lineage COVID-19 vaccine formulations -- the same as last year's -- with monovalent LP.8.1 lineage as a suitable alternative formulation.

The rollout of updated Covid vaccines for healthy children and adults this fall is likely to be delayed after the FDA said it will require another clinical trial.